Juno Therapeutics is a clinical-stage company developing novel cellular immunotherapies based on two distinct and complementary platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Our goal is to revolutionize medicine by re-engaging the body’s immune system to treat cancer.

Our Science

The use of human T cells as therapeutics to re-engage the immune system has the potential to revolutionize the way cancer is treated. Juno’s technologies genetically engineer a patient’s own T cells to recognize and kill cancer cells. These cellular therapies have the potential to be effective regardless of the type of previous treatments patients have experienced and may avoid the long-term side effects associated with current treatments. We use two different technologies to target cancer cells and activate T cells, CARs and TCRs.

Juno Welcomes Stage Cell Therapeutics

Juno Therapeutics warmly welcomes Stage Cell Therapeutics GmbH (“Stage”), a privately held biotechnology company based in Munich and Göttingen, Germany. This acquisition furthers our strategy of being a world leader in process development and the manufacturing of cellular therapies. Stage will become a wholly-owned German subsidiary under the name Juno Therapeutics GmbH.  Juno welcomes our new colleagues in Germany to the Juno family.

More about Juno Therapeutics GmbH, formerly Stage Cell Therapeutics GmbH. Click here

Learn More

Juno Therapeutics

Chimeric Antigen Receptors (CARs)

Chimeric Antigen Receptor (CAR) technology directs T cells to recognize cancer cells based on expression of specific cell surface proteins.

T Cell Receptors (TCRs)

High-affinity TCR technology provides T cells with a specific T cell receptor that recognizes cancer cells based on expression of specific proteins inside the cell or on the cell surface.

For Patients

T cell immunotherapy using CAR and TCR technologies have shown promising results in early clinical trials and may offer new options for patients with cancer.